Header:
TEXAS ADMINISTRATIVE CODE
TITLE 25. HEALTH SERVICES
PART 1. DEPARTMENT OF STATE HEALTH SERVICES
CHAPTER 97. COMMUNICABLE DISEASES
SUBCHAPTER A. CONTROL OF COMMUNICABLE DISEASES
Date:
03/17/2014
Document:
§ 97.3. What Condition to Report and What Isolates to Report or Submit
(a) Humans.
(1) Identification of notifiable conditions.
(A) A summary list of notifiable conditions and reporting time frames is published on the Department of State Health Services web site at http://www.dshs.state.tx.us/idcu/. Copies are filed in the Emerging and Acute Infectious Disease Branch, Department of State Health Services, 1100 West 49th Street, Austin, Texas 78756.
(B) Repetitive test results from the same patient do not need to be reported except those for mycobacterial infec-tions.
(2) Notifiable conditions or isolates.
(A) Confirmed and suspected human cases of the following diseases/infections are reportable: acquired immune deficiency syndrome (AIDS); amebiasis; amebic meningitis and encephalitis; anaplasmosis; anthrax; arboviral infections caused by California serogroup virus, Eastern equine encephalitis (EEE) virus, Powassan virus, St. Louis encephalitis (SLE) virus, Western equine encephalitis (WEE) virus, and West Nile (WN) virus; babesiosis; botulism-adult and infant; brucellosis; campylobacteriosis; Chagas' disease; chancroid; chickenpox (varicella); Chlamydia trachomatis infection; Creutzfeldt-Jakob disease (CJD); cryptosporidiosis; cyclosporiasis; dengue; diphtheria; ehrlichiosis; shiga-toxin producing Escherichia coli infection; gonorrhea; Hansen's disease (leprosy); Haemophilus influenzae type b infection, invasive; hantavirus infection; hemolytic uremic syndrome (HUS); hepatitis A, B, C, and E, (acute); hepatitis B, (acute and chronic) identified prenatally or at delivery; perinatal hepatitis B infection; human immunodeficiency virus (HIV) infection; influenza-associated pediatric mortality; legionellosis; leishmaniasis; listeriosis; Lyme disease; malaria; mea-sles (rubeola); meningococcal infection, invasive; novel influenza; mumps; pertussis; plague; poliomyelitis, acute para-lytic; poliovirus infection, non-paralytic; Q fever; rabies; relapsing fever; rubella (including congenital); salmonellosis, including typhoid fever; severe acute respiratory syndrome (SARS) as defined by the United States Centers for Disease Control and Prevention; shigellosis; smallpox; spotted fever group rickettsioses (such as Rocky Mountain spotted fe-ver); streptococcal disease: invasive group A, invasive group B, or invasive Streptococcus pneumoniae; syphilis; Taenia solium and undifferentiated Taenia infections, including cysticercosis; tetanus; trichinosis; tuberculosis; tularemia; typhus; Vibrio infection, including cholera (specify species); viral hemorrhagic fevers; yellow fever; yersiniosis; and vancomycin-intermediate resistant Staphylococcus aureus (VISA), and vancomycin-resistant Staphylococcus aureus (VRSA).
(B) In addition to individual case reports, any outbreak, exotic disease, or unusual group expression of disease that may be of public health concern should be reported by the most expeditious means.
(3) Minimal reportable information requirements. The minimal information that shall be reported for each disease is as follows:
(A) AIDS, chancroid, Chlamydia trachomatis infection, gonorrhea, HIV infection, and syphilis shall be reported in accordance with §§ 97.132 - 97.134 of this title (relating to Sexually Transmitted Diseases Including Acquired Immune Deficiency Syndrome (AIDS) and Human Immunodeficiency Virus (HIV));
(B) for tuberculosis disease - complete name, date of birth, physical address and county of residence, information on which diagnosis was based or suspected. In addition, if known, radiographic or diagnostic imaging results and date(s); all information necessary to complete the most recent versions of forms TB 400 A & B (Report of Case and Patient Services), TB 340 (Report of Contacts) and TB 341 (Continuation of Report of Contacts); laboratory results used to guide prescribing, monitoring or modifying antibiotic treatment regimens for tuberculosis to include, but not limited to, liver function studies, renal function studies, and serum drug levels; pathology reports related to diagnostic evaluations of tuberculosis; reports of imaging or radiographic studies; records of hospital or outpatient care to include, but not limited to, histories and physical examinations, discharge summaries and progress notes; records of medication administration to include, but not limited to, directly observed therapy (DOT) records, and drug toxicity and monitoring records; a listing of other patient medications to evaluate the potential for drug-drug interactions; and copies of court documents related to court ordered management of tuberculosis.
(C) for contacts to a known case of tuberculosis - complete name; date of birth; physical address; county of resi-dence; and all information necessary to complete the most recent versions of forms TB 400 A & B (Report of Case and Patient Services), TB 340 (Report of Contacts), and TB 341 (Continuation of Report of Contacts);
(D) for other persons identified with latent TB infection - complete name; date of birth; physical address and county of residence; and diagnostic information;
(E) for hepatitis B (chronic and acute) identified prenatally or at delivery - mother's name, address, telephone number, age, date of birth, sex, race and ethnicity, preferred language, hepatitis B laboratory test results; estimated delivery date or date and time of birth; name and phone number of delivery hospital or planned delivery hospital; name of infant; name, phone number, and address of medical provider for infant; date, time, formulation, dose, man-ufacturer, and lot number of hepatitis B vaccine and hepatitis B immune globulin administered to infant;
(F) for hepatitis A, B, C, and E - name, address, telephone number, age, date of birth, sex, race and ethnicity, dis-ease, diagnostic indicators (diagnostic lab results, including all positive and negative hepatitis panel results, liver func-tion tests, and symptoms), date of onset, pregnancy status, and physician name, address, and telephone number;
(G) for perinatal hepatitis B - name of infant; date of birth; sex; race; ethnicity; name, phone number and address of medical provider for infant; date, time, formulation, dose, manufacturer, and lot number of hepatitis B vaccine and hepatitis B immune globulin administered to infant, hepatitis B laboratory test results;
(H) for chickenpox - name, date of birth, sex, race and ethnicity, address, date of onset, and varicella vaccination history;
(I) for VISA; and VRSA - name, address, telephone number, age, date of birth, sex, race and ethnicity, disease, di-agnostic indicators (diagnostic lab results, anatomic site of culture, and clinical indicators), date of onset, and physician name, address, and telephone number;
(J) for Hansen's disease - name; date of birth; sex; race and ethnicity; social security number; disease type; place of birth; address; telephone number; date entered Texas; date entered U.S.; education/employment; insurance status; location and inclusive dates of residence outside U.S.; date of onset and history prior to diagnosis; date of initial biopsy and result; date initial drugs prescribed and name of drugs; name, date of birth and relationship of household contacts; and name, address, and telephone number of physician;
(K) for novel influenza investigations occurring during an influenza pandemic--minimal reportable information on individual cases, a subset of cases or aggregate data will be specified by the department;
(L) for all other notifiable conditions listed in paragraph (2)(A) of this subsection - name, address, telephone number, age, date of birth, sex, race and ethnicity, disease, diagnostic indicators (diagnostic lab results and specimen source, and clinical indicators), date of onset, and physician name, address, and telephone number; and
(M) other information may be required as part of an investigation in accordance with Texas Health and Safety Code, § 81.061.
(4) Diseases requiring submission of cultures. For all anthrax (Bacillus anthracis), botulism-adult and infant (Clos-tridium botulinum), brucellosis (Brucella species), E.coli 0157:H7, isolates or specimens from cases where Shiga-toxin activity is demonstrated, Listeria monocytogenes, meningococcal infection, invasive (Neisseria meningitides from normally sterile sites), plague (Yersinia pestis), tuberculosis (Mycobacterium tuberculosis complex), tularemia (Fran-cisella tularensis), all Staphylococcus aureus with a vancomycin MIC greater than 2 g/mL, and Vibrio species - pure cultures shall be submitted accompanied by a current department Specimen Submission Form.
(5) Laboratory reports. Reports from laboratories shall include name, patient identification number, address, tel-ephone number, age, date of birth, sex, race and ethnicity, specimen submitter name, address, and phone number, specimen type, date specimen collected, disease test and test result, normal test range, date of test report, and physi-cian name and telephone number.
(b) Animals.
(1) Clinically diagnosed or laboratory-confirmed animal cases of the following diseases are reportable: anthrax, arboviral encephalitis, Chagas' disease, Mycobacterium tuberculosis infection in animals other than those housed in research facilities, plague, and psittacosis. Also, all non-negative rabies tests performed on animals from Texas at la-boratories located outside of Texas shall be reported; all non-negative rabies tests performed in Texas will be reported by the laboratory conducting the testing. In addition to individual case reports, any outbreak, exotic disease, or unusual group expression of disease which may be of public health concern should be reported by the most expeditious means.
(2) The minimal information that shall be reported for each disease includes species and number of animals af-fected, disease or condition, name and phone number of the veterinarian or other person in attendance, and the ani-mal(s) owner's name, address, and phone number. Other information may be required as part of an investigation in accordance with Texas Health and Safety Code, § 81.061.
|